Influence of prothymosin-α on HIV-1 target cells

Annals of the New York Academy of Sciences

Volumn 1112, Issue , 2007, Pages 269-285

  Mosoian, Arevik ^a   Teixeira, Avelino ^a   Burns, Colin S ^b   Khitrov, Gregory ^a   Zhang, Weijia ^a   Gusella, Luca ^a   Klotman, Paul ^a   Klotman, Mary ^a  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^b EAST CAROLINA UNIVERSITY   (United States)

Author keywords

CEBP alpha; Dendritic cells; HIV 1; IFN; IRF1; Macrophages; Prothymosin alpha; RUNX3; STAT2

Indexed keywords

ALPHA INTERFERON; INTERFERON REGULATORY FACTOR 1; MESSENGER RNA; PROTEIN SERINE THREONINE KINASE; PROTHYMOSIN ALPHA; RANTES; TRANSCRIPTION FACTOR;

ANTIVIRAL ACTIVITY; CD8+ T LYMPHOCYTE; CONFERENCE PAPER; CONTROLLED STUDY; GENE; GENETIC REGULATION; HOST CELL; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; PROTEIN INDUCTION; SUPERNATANT; TARGET CELL; VIRUS REPLICATION; VIRUS TRANSCRIPTION;

HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 35349000512     PISSN: 00778923     EISSN: 17496632     Source Type: Book Series    
DOI: 10.1196/annals.1415.043     Document Type: Conference Paper

References (39)

1. TSITSILONI, O.E. et al. 1993. Expression of alpha-thymosins in human tissues in normal and abnormal growth. Proc. Natl. Acad. Sci. USA 90: 9504-9507.
2. VARTAPETIAN, A.B. 1992. Myc proteins, prothymosin alpha, and cell division. Biokhimiia 57: 477-478.
3. SBURLATI, A.R. et al. 1991. Prothymosin alpha antisense oligomers inhibit myeloma cell division. Proc. Natl. Acad. Sci. USA 88: 253-257.
4. RODRIGUEZ, P. et al. 1998. Overexpression of prothymosin alpha accelerates proliferation and retards differentiation in HL-60 cells. Biochem. J. 331(Pt 3): 753-761.
5. SHIAU, A.L. et al. 2001. Retrovirus-mediated transfer of prothymosin gene inhibits tumor growth and prolongs survival in murine bladder cancer. Gene Ther. 8: 1609-1617.
6. DIAZ-JULLIEN, C. et al. 1996. Prothymosin alpha binds histones in vitro and shows activity in nucleosome assembly assay. Biochim. Biophys. Acta 1296: 219-227.
7. KNIGHT, J.S. et al. 2003. Epstein-Barr virus nuclear antigen 3C recruits histone deacetylase activity and associates with the corepressors mSin3A and NCoR in human B-cell lines. J. Virol. 77: 4261-4672.
8. KARETSOU, Z. et al. 2002. Prothymosin alpha interacts with the CREB-binding protein and potentiates transcription. EMBO Rep. 3: 361-366.
9. KARETSOU, Z. et al. 1998. Prothymosin alpha modulates the interaction of histone H1 with chromatin. Nucleic Acids Res. 26: 3111-3118.
10. FREIRE, J. et al. 2001. Identification of nuclear-import and cell-cycle regulatory proteins that bind to prothymosin alpha. Biochem. Cell Biol. 79: 123-131.
11. TRUMBORE, M.W. & S.L. BERGER. 2000. Prothymosin alpha is a nonspecific facilitator of nuclear processes: studies of run-on transcription. Protein Expr. Purif. 20: 414-420.
12. TZEHOVAL, E. et al. 1989. Thymosins alpha 1 and beta 4 potentiate the antigen-presenting capacity of macrophages. Immunopharmacology 18: 107-113.
13. LEICHTLING, K.D. et al 1990. Thymosin alpha 1 modulates the expression of high affinity interleukin-2 receptors on normal human lymphocytes. Int. J. Immunopharmacol. 12: 19-29.
14. ROMANI, L. et al. 2004. Thymosin alpha 1 activates dendritic cells for antifungal Th1 resistance through toll-like receptor signaling. Blood 103: 4232-4239.
15. MOODY, T.W. et al. 2000. Thymosinalpha1 is chemopreventive for lung adenoma formation in A/J mice. Cancer Lett. 155: 121-127.
16. MOSOIAN, A. et al. 2006. Novel function of prothymosin alpha as a potent inhibitor of human immunodeficiency virus type 1 gene expression in primary macrophages. J. Virol. 80: 9200-9206.
17. WILSON, C.L. et al. 2006. Purification and characterization of the central segment of prothymosin-alpha: methodology for handling highly acidic peptides. J. Pept. Sci. 12: 721-725.
18. MOSOIAN, A. et al. 2000. CD8+ cell lines isolated from HIV-1-infected children have potent soluble HIV-1 inhibitory activity that differs from beta-chemokines. Viral Immunol. 13: 481-495.
19. EVSTAFIEVA, A.G. et al. 1995. Overproduction in Escherichia coli, purification and properties of human prothymosin alpha. Eur. J. Biochem. 231: 639-643.
20. FRANCO, F.J. et al. 1992. Thymosin alpha 1 is a native peptide in several tissues. Biochim. Biophys. Acta 1120: 43-48.
21. UVERSKY, V.N. et al. 2000. Zn(2+)-mediated structure formation and compaction of the "natively unfolded" human prothymosin alpha. Biochem. Biophys. Res. Commun. 267: 663-668.
22. HENDERSON, A.J. & K.L. CALAME. 1997. CCAAT/enhancer binding protein (C/EBP) sites are required for HIV-1 replication in primary macrophages but not CD4(+) T cells. Proc. Natl. Acad. Sci. USA 94: 8714-8719.
23. LAIOSA, C.V. et al. 2006. Reprogramming of committed T cell progenitors to macrophages and dendritic cells by C/EBP alpha and PU.1 transcription factors. Immunity 25: 731-744.
24. HOTTIGER, M.O. et al. 1998. Modulation of cytokine-induced HIV gene expression by competitive binding of transcription factors to the coactivator p300. EMBO J. 17: 3124-3134.
25. BATTISTINI, A., et al. 2002. IRF regulation of HIV-1 long terminal repeat activity. J. Interferon Cytokine Res. 22: 27-37.
26. HASEGAWA, K. et al. 2007. Restoration of RUNX3 enhances transforming growth factor-beta-dependent p21 expression in a biliary tract cancer cell line. Cancer Sci. 98: 838-843.
27. ADELSON, M.E. et al. 1999. Inhibition of human immunodeficiency virus (HIV-1) replication in SupT1 cells transduced with an HIV-1 LTR-driven PKR cDNA construct. Eur. J. Biochem. 264: 806-815.
28. MUTO, N.F. et al. 1999. Inhibition of replication of reactivated human immunodeficiency virus type 1 (HIV-1) in latently infected U1 cells transduced with an HIV-1 long terminal repeat-driven PKR cDNA construct. J. Virol. 73: 9021-9028.
29. MEYLAN, P.R. et al. 1993. Mechanisms for the inhibition of HIV replication by interferons-alpha, -beta, and -gamma in primary human macrophages. Virology 193: 138-148.
30. ROGEZ, C. et al. 2003. Anti-human immunodeficiency virus activity of tau interferon in human macrophages: involvement of cellular factors and beta-chemokines. J. Virol. 77: 12914-12920.
31. COSTOPOULOU, D. et al. 1998. Direct ELISA method for the specific determination of prothymosin alpha in human specimens. J. Immunoassay 19: 295-316.
32. CORDERO, O.J. et al. 1992. On the anomalous behaviour on gel-filtration and SDS-electrophoresis of prothymosin-alpha. Biochem. Int. 28: 1117-1124.
33. MARSILI, G. et al. 2004. Role of acetylases and deacetylase inhibitors in IRF1-mediated HIV-1 long terminal repeat transcription. Ann. N. Y. Acad. Sci. 1030: 636-643.
34. CHANG, T.L. et al. 2003. CAF-mediated human immunodeficiency virus (HIV) type 1 transcriptional inhibition is distinct from alpha-defensin-1 HIV inhibition. J. Virol. 77: 6777-6784.
35. VIEILLARD, V. et al. 1994. Blocking of retroviral infection at a step prior to reverse transcription in cells transformed to constitutively express interferon beta. Proc. Natl. Acad. Sci. USA 91: 2689-2693.
36. SHIRAZI, Y. & P.M. PITHA. 1993. Interferon alpha-mediated inhibition of human immunodeficiency virus type 1 provirus synthesis in T-cells. Virology 193: 303-312.
37. COCCIA, E.M., B. KRUST & A.G. HOVANESSIAN. 1994. Specific inhibition of viral protein synthesis in HIV-infected cells in response to interferon treatment. J. Biol. Chem. 269: 23087-23094.
38. POLI, G. et al. 1989. Interferon-alpha but not AZT suppresses HIV expression in chronically infected cell lines. Science 244: 575-577.
39. PENG, G. et al. 2006. Induction of APOBEC3 family proteins, a defensive maneuver underlying interferon-induced anti-HIV-1 activity. J. Exp. Med. 203: 41-46.